Insulin Giants' Antitrust Victory On Shaky Ground At 2nd Circ.

A major legal triumph for manufacturers of wildly popular medications treating diabetes and obesity suddenly looked precarious Friday at the Second Circuit, where judges sounded open to reviving a proposed class...

Already a subscriber? Click here to view full article